Core Insights - PDS Biotechnology Corporation is seeking an expedited approval pathway from the FDA for its immunotherapy PDS0101 targeting HPV16-positive head and neck cancer, projected to be the most prevalent type of head and neck cancer in the US by the mid-2030s [1][2] Company Overview - PDS Biotechnology is a late-stage immunotherapy company focused on innovative cancer treatments, particularly through its lead program PDS0101, which is being developed in combination with standard immune checkpoint inhibitors [4] Clinical Trials - The VERSATILE-002 trial has shown promising results, reporting a median overall survival (mOS) of 39.3 months and a median progression-free survival (PFS) of 6.3 months, leading to a proposed amendment in the ongoing VERSATILE-003 trial to include PFS as an earlier primary endpoint [1][2][3] - The VERSATILE-002 trial is an open-label, multi-center Phase 2 study evaluating the safety and efficacy of PDS0101 in combination with pembrolizumab for patients with unresectable, recurrent, or metastatic HPV16-positive head and neck cancer [3] Regulatory Strategy - The company plans to meet with the FDA to discuss changes to the current trial protocol, aiming to shorten the trial duration by making PFS an earlier primary endpoint, which could facilitate an accelerated approval submission [1][2]

Core Points - The Chinese Entrepreneurs Cultural Festival is recognized as one of the "World's Top Ten Most Influential Root-Seeking Cultural Events" and will take place in Shangqiu on October 29, 2025 [1] - The festival aims to enhance the cultural brand of "Shangqiu - the Source of Merchants" through various activities, promoting industrial connectivity and resource matching [4] Historical Context - Since its inception in 2006, the festival has been held nine times, with Shangqiu regarded as the birthplace of Chinese commerce [5] - The region has historical significance in the development of commerce, with notable figures and practices that laid the foundation for Chinese business culture [5]

Core Insights - Moleculin Biotech, Inc. has been granted an Australian patent for preliposomal Annamycin lyophilizates, enhancing its global intellectual property portfolio with a base patent term extending until June 2040 [1][2] - Annamycin is being developed as a non-cardiotoxic anthracycline for treating acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases, with potential applications for various other cancers [2][4] - The company has initiated the MIRACLE trial, a Phase 3 study evaluating Annamycin in combination with cytarabine for relapsed or refractory AML, following a successful Phase 1B/2 study [5] Patent and Intellectual Property - The newly granted Australian patent covers preliposomal Annamycin with improved stability and high purity, contributing to the company's competitive position in oncology [1][2] - The patent family includes expected Canadian patents and previously issued U.S. and European patents, with additional applications pending in major jurisdictions worldwide [2] Drug Development and Clinical Trials - Annamycin has received Fast Track Status and Orphan Drug Designation from the FDA for relapsed or refractory AML and STS lung metastases, as well as Orphan Drug Designation from the EMA [3] - The MIRACLE trial aims to evaluate the efficacy of Annamycin in combination with cytarabine, which is expected to de-risk the development pathway towards potential approval [5] Additional Pipeline Candidates - The company is also developing WP1066, an immune/transcription modulator targeting various cancers, and WP1122, an antimetabolite for treating pathogenic viruses and certain cancer indications [6]

Core Insights - Argo Corporation's Smart Routing™ system has led to a significant increase in monthly transfers at Bradford GO Station, with a 5.5x rise compared to the 12-month baseline prior to its launch in April 2025 [1][2] - The average total daily ridership in Bradford West Gwillimbury more than doubled within two months of the Smart Routing™ system's implementation, indicating its effectiveness in enhancing transit usage [2] - The integration of real-time GO Transit feeds and Ontario's PRESTO fare system further enhances the Smart Routing™ system's capability to improve existing transit infrastructure [2] Group 1 - The increase in connections to Bradford GO Station demonstrates the effectiveness of Argo's Smart Routing™ system in complementing existing public transit networks [1][2] - Public data indicates that in 2019, approximately 71% of GO customers accessed their origin station by car, highlighting the need for improved first/last-mile transit connections [3] - The growth in transit ridership benefits both riders and taxpayers by reducing personal car and rideshare costs while alleviating pressure on publicly-funded parking infrastructure [3] Group 2 - CEO Praveen Arichandran emphasized that the results in Bradford West Gwillimbury validate the company's vision for a future where public transit is the most convenient travel option [4] - Argo aims to create a vertically and publicly integrated city transit system that enhances public transportation and provides intelligently routed vehicles to meet urban mobility needs [4]

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES MONTREAL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Osisko Development Corp. (NYSE: ODV, TSXV: ODV) ("Osisko Development" or the "Company") is pleased to announce the successful closing of its previously-announced oversubscribed private placement offering of 15,409,798 common shares of the Company (the "Common Shares") for aggregate gross proceeds of approximately C$82.5 million (the "Offering"). The Offering is compr ...

Company Overview - CYIOS Corporation LLC is a Nevada-registered holding company focused on acquisitions, modernization, and technology integration in the healthcare and medical supply sectors [1][5] - The company is actively expanding its presence in the U.S. medical distribution sector through its subsidiary Noir Medical Supplies, emphasizing operational excellence and sustainable profitability [5] Strategic Initiatives - CYIOS has engaged Atlanta Capital Partners, LLC to lead a renewed investor relations strategy aimed at enhancing visibility and communication within the investment community [1][4] - The current strategic plan includes reducing legacy debt, advancing targeted healthcare acquisitions, and scaling the AI-powered SaaS platform, CyioIQ [3] - The company aims to qualify for OTCQB and Nasdaq listings supported by a strengthened balance sheet [3] Growth and Transformation - The partnership with Atlanta Capital Partners is expected to elevate CYIOS's profile among investors seeking transformation-stage opportunities in high-demand sectors like healthcare technology [4] - Key initiatives under this partnership include expanded outreach to various investor types, consistent corporate updates, increased financial media exposure, and strategic event participation [4]

SHENZHEN, China, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Jayud Global Logistics Limited (NASDAQ: JYD) ("Jayud" or the "Company"), a leading end-to-end supply chain solution provider based in Shenzhen, specializing in cross-border logistics, today announced that it has entered into multiple international freight logistics agreements with major multinational corporations. These include Chongqing Chuandong Chemical (Group) Limited, established in 1958, a leading chemical manufacture in Chongqing and ranked Top 10 En ...

Kennewick, WA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) today announced enhanced cooperation with Exubrion Therapeutics to advance the use of targeted radioactive isotope technology for multiple indications in companion animals. The two companies have agreed to broaden their joint efforts in several key areas — including shared clinic relationships, licensing coordination, and manufacturing optimization. These initiatives build upon prior collaborations involving device classification, dev ...

Core Points - Aterian, Inc. announced the availability of its hOmeLabs brand line of dehumidifiers on Home Depot's website, enhancing its digital presence and sales strategy [1][3] - The hOmeLabs dehumidifiers are designed for improved health and efficiency, featuring user-friendly controls, Energy Star ratings, portability, and Wi-Fi capabilities [2] - Aterian aims to strengthen its brand presence and omni-channel sales approach through this partnership with Home Depot, a leading retail brand in the U.S. [3] Company Overview - Aterian, Inc. is a consumer products company that develops and acquires e-commerce brands across various categories, including home appliances and air quality devices [5] - The company sells products on major online marketplaces such as Amazon, Walmart, and Target, as well as through its own direct-to-consumer channels [5] - Aterian's brand portfolio includes well-known names like Mueller Living, PurSteam, hOmeLabs, and Squatty Potty [5] Home Depot Overview - Home Depot is the largest home improvement specialty retailer globally, operating over 2,353 retail stores and more than 325 distribution centers [4] - The company employs over 470,000 associates and is included in the Dow Jones Industrial Average and S&P 500 index [4]

Core Points - Alliance Entertainment Holding Corporation will hold a conference call on November 12, 2025, at 4:30 p.m. Eastern Time to discuss its Q1 fiscal year 2026 results [1] - The call will be hosted by CEO Jeff Walker, CFO Amanda Gnecco, and Executive Chairman Bruce Ogilvie, followed by a Q&A session [2] - The company is a leading distributor and logistics provider in the entertainment and pop culture collectibles industry, offering over 340,000 unique SKUs to more than 35,000 retail and e-commerce storefronts [4] Company Overview - Alliance Entertainment provides a vast selection of physical media, including over 57,300 exclusive titles across various formats such as CDs, vinyl LPs, DVDs, and video games [4] - The company also offers licensed merchandise, toys, retro gaming products, and collectibles, enhancing its position in the market [4] - Alliance's operational expertise and exclusive licensing partnerships enable it to serve as a trusted partner to top entertainment brands and retailers [4]